(R)-Bicalutamide |
 |
| PRODUCT LINE | DNA Regulation / Transcription |
|
|
| PRODUCT FAMILIES | Androgens & Androgen Receptors / Related Products |
|
|
|
| Ordering Information |
|
| Product Numbers | Format | Size | Unit Price | Quantity | | | LKT-B3210-M100 |
|
100 mg | | | | | LKT-B3210-M250 |
|
250 mg | | | | | LKT-B3210-G001 |
|
1 g | | | | | | |
|
|
| Product Specification |
|
|
| FORMULA: | C18H14F4N2O4S |
|
|
| |
|
| MW: | 430.4 |
|
|
| |
|
| CAS NUMBER: | 113299-40-4 |
|
|
|
|
| Product Description |
Chiral nonsteroidal antiandrogen which has been shown to inhibit CYP3A4, with lesser effect on CYP2C9, 2C19 and 2D6. |
|
| | Product Specific Literature References | | Bicalutamide: clinical pharmacokinetics and metabolism: I.D. Cockshott; Clin. Pharmacokinet. 43, 855 (2004) Abstract |
|
|
|
|
| RELATED PRODUCT GROUPS |
Cancer > Antitumor Reagents > Antitumor Agents (Hormone-related) / Cancer > Antitumor Reagents > Antitumor Agents (Apoptosis Inducers) |
|
|
|
